Isolation, NMR Characterization, and Comparative In Vitro Antioxidant Evaluation of Resveratrol from Grape Seeds (Vitis vinifera L.)
Abstract
Objective: The present study aimed to isolate, characterize, and evaluate the in vitro antioxidant potential of resveratrol from grape seeds (Vitis vinifera L.) obtained from local markets in Erzincan, Türkiye. It is hypothesized that the unique microclimate of that region enhances the bioactive profile of local grape varieties, making them a significant source of natural antioxidants.
Methods: Grape seeds (500 g) were extracted using 100% methanol via reflux for 4 hours (three replicates). The crude extract (30 g) underwent liquid-liquid extraction with ethyl acetate to yield a concentrated phenolic fraction (2 g). For isolation, Sephadex LH-20 adsorbent was used as the stationary phase and eluted with methanol. Structural characterization was conducted using 1H and 13C NMR spectroscopy. The antioxidant capacity of the isolated resveratrol was determined through DPPH and ABTS radical scavenging assays, comparing results with standard antioxidants (Trolox, BHA, BHT, and Ascorbic acid).
Results: Chromatographic purification yielded 10 mg of pure trans-resveratrol. The structure was firmly verified by NMR spectroscopy, with the high olefinic coupling constant (J = 16.3 Hz) suggesting the trans structure. In antioxidant experiments, Trans-resveratrol demonstrated notable DPPH radical scavenging action (IC₅₀ = 17.33 ± 1.22 µg/mL). Trans-resveratrol outperformed Trolox (7.22 ± 0.24 µg/mL) and ascorbic acid (8.22 ± 0.37 µg/mL) in the ABTS test, with an IC₅₀ of 6.84 ± 0.47 µg/mL.
Conclusion: The findings demonstrate that grape seeds from Erzincan markets are an excellent source of highly bioactive trans-resveratrol. The isolated compound exhibited exceptional antioxidant efficiency, particularly in the ABTS assay where it surpassed several commercial standards. These results suggest that local grape varieties possess significant potential as natural sources for high-purity bioactive agents in the nutraceutical and pharmaceutical sectors.
Keywords
References
- Aydın, T., Çakır, A., Kazaz, C., Bayrak, N., Bayır, Y., & Taşkesenligil, Y. (2014). Insecticidal metabolites from the rhizomes of Veratrum album against adults of Colorado potato beetle, Leptinotarsa decemlineata. Chemistry & Biodiversity, 11(8), 1192–1204. https://doi.org/10.1002/cbdv.201300407
- Benzie, I. F., & Strain, J. J. (1996). The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay. Analytical Biochemistry, 239(1), 70–76. https://doi.org/10.1006/abio.1996.0292
- Coklar, H. (2017). Antioxidant capacity and phenolic profile of berry, seed, and skin of Ekşikara (Vitis vinifera L.) grape: Influence of harvest year and altitude. International Journal of Food Properties, 20(9), 2071–2087. https://doi.org/10.1080/10942912.2016.1230870
- Floegel, A., Kim, D.-O., Chung, S.-J., Koo, S. I., & Chun, O. K. (2011). Comparison of ABTS/DPPH assays to measure antioxidant capacity in popular antioxidant-rich US foods. Journal of Food Composition and Analysis, 24(7), 1043–1048. https://doi.org/10.1016/j.jfca.2011.01.008
- Galiniak, S., Aebisher, D., & Bartusik-Aebisher, D. (2019). Health benefits of resveratrol administration. Acta Biochimica Polonica, 66(1), 13–21. https://doi.org/10.18388/abp.2018_2749
- Gözcü, S., & Atmaca, M. (2025). Antioxidant potential and phenolic content of Plantago major. Current Research in Health Sciences, 2(1), 27–32. https://doi.org/10.62425/crihs.1628360
- Gülçin, İ. (2010). Antioxidant properties of resveratrol: A structure–activity insight. Innovative Food Science & Emerging Technologies, 11(1), 210–218. https://doi.org/10.1016/j.ifset.2009.07.002
- Hansen, P. E. (2021). NMR of natural products as potential drugs. Molecules, 26(12), 3763. https://doi.org/10.3390/molecules26123763
- Kovacic, P., & Somanathan, R. (2010). Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling, and safety. Oxidative Medicine and Cellular Longevity, 3(2), 86–100. https://doi.org/10.4161/oxim.3.2.11147
- Pezzuto, J. M. (2018). Resveratrol: Twenty years of growth, development and controversy. Biomolecules & Therapeutics, 27(1), 1–14. https://doi.org/10.4062/biomolther.2018.176
- Pryor, W. A., Houk, K. N., Foote, C. S., Fukuto, J. M., Ignarro, L. J., Squadrito, G. L., & Davies, K. J. A. (2006). Free radical biology and medicine: It’s a gas, man! American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 291(3), R491–R511. https://doi.org/10.1152/ajpregu.00614.2005
- Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., & Rice-Evans, C. (1999). Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radical Biology and Medicine, 26(9–10), 1231–1237. https://doi.org/10.1016/S0891-5849(98)00315-3
- Sajish, M., & Schimmel, P. (2015). A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature, 519(7543), 370–373. https://doi.org/10.1038/nature14028
- Samad, N. B., Debnath, T., Ye, M., Hasnat, M. A., & Lim, B. O. (2014). In vitro antioxidant and anti-inflammatory activities of Korean blueberry (Vaccinium corymbosum L.) extracts. Asian Pacific Journal of Tropical Biomedicine, 4(10), 807–815. https://doi.org/10.12980/APJTB.4.2014C1008
- Şimşek, S., Akşit, H., Köksal, E., & Altay, A. (2026). Antioxidant, antidiabetic, antiproliferative activities, and verbascoside content of four endemic Verbascum species. New Zealand Journal of Botany, 64(1), e70023. https://doi.org/10.1002/nzb2.70023
- Truong, V. L., Jun, M., & Jeong, W. S. (2018). Role of resveratrol in regulation of cellular defense systems against oxidative stress. BioFactors, 44(1), 36–49. https://doi.org/10.1002/biof.1399
- Xia, E. Q., Deng, G. F., Guo, Y. J., & Li, H. B. (2010). Biological activities of polyphenols from grapes. International Journal of Molecular Sciences, 11(2), 622–646. https://doi.org/10.3390/ijms11020622
Details
| Primary Language | English |
|---|---|
| Subjects | Pharmacognosy |
| Journal Section | Research Article |
| Authors | |
| Submission Date | February 16, 2026 |
| Acceptance Date | April 17, 2026 |
| Early Pub Date | April 24, 2026 |
| Publication Date | April 24, 2026 |
| DOI | https://doi.org/10.62425/rtpharma.1887856 |
| IZ | https://izlik.org/JA87RD46AW |
| Published in Issue | Year 2026 Volume: 4 Issue: 1 |
Aim & Scope
Recent Trends in Pharmacology is a scientific periodical in the field of pharmacology and medicine, which includes original articles, case reports and reviews. It aims to provide online free access to the pharmacology and medical community articles prepared by well-known scientists with a high h-index in the English language.
Recent Trends in Pharmacology is a peer-reviewed, open-access, online-only journal published by Atatürk University.
The journal is published triannual in both English, with articles released in April, August, and December.
Recent Trends in Pharmacology aims to publish studies of the highest scientific caliber in the field of pharmacology and medicine.
Recent Trends in Pharmacology publishes research article, review, meta-analysis, rare case reports, and letter to the editor articles that will contribute to the literature on pharmacology and medicine. The main purpose of the journal is to disseminate the scientific knowledge produced in the field of pharmacology, experimental and clinical therapeutics to a wide platform. In doing so, the journal aims to bring together researchers, educational practitioners and policy makers at a common intersection.
The target audience of the journal consists of researchers who are interested in or working in the field of pharmacology and medicine.
Author Guidelines
You can access the Article Submission Guidelines here.
You can access the Article Submission Guidelines video here.
You can download the reference style for use in Mendeley and Zotero here.
For comprehensive information regarding the journal's policies on submission, peer-review, publication, and ethical standards, kindly visit the Policies page. Similarly, for detailed information about the journal, please visit the Aims and Scope page.
It is strongly advised to review the journal's policies before submitting any manuscripts to ensure compliance with the journal's guidelines.
Manuscripts submitted for evaluation should be original and not previously presented or published in any electronic or print medium. If a manuscript was previously presented at a conference or meeting, authors should provide detailed information about the event, including the name, date, and location of the organization.
Manuscripts should be prepared in accordance with ICMJE-Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated in January 2024).
Authors are required to prepare manuscripts in accordance with the relevant guideline listed below:
• Randomized research studies and clinical trials: CONSORT guidelines (for protocols, please see the SPIRIT guidance)
• Observational original research studies: STROBE guidelines
• Studies on diagnostic accuracy: STARD guidelines
• Experimental animal studies: ARRIVE guidelines and Guide for the Care and Use of Laboratory Animals, 8th edition
• Nonrandomized evaluations of behavioral and public health interventions: TREND guidelines
• Case report: the CARE case report guidelines
• Genetic association studies: STREGA
• Qualitative research: SRQR guidelines
To find the right guideline for your research, please complete the questionnaire by Equator Network here.
Recent Trends in Pharmacology encourages authors to follow the ‘Sex and Gender Equity in Research – SAGER – guidelines’ when preparing their manuscripts to promote the inclusion of sex and gender considerations in research. Before submission, authors can consult EASE Guidelines for Authors and Translators to produce clear, concise and accurate manuscripts that are easy to understand and free of common errors and pitfalls.
The style of manuscripts should follow the Publication Manual of the American Psychological Association (APA), Seventh Edition (2020).
Manuscripts can only be submitted through the journal’s online manuscript submission and evaluation system. Manuscripts submitted via any other medium and submissions by anyone other than one of the authors will not be evaluated.
In addition to the manuscript files, authors are required to submit the following during the initial submission:
· Copyright Agreement and Acknowledgement of Authorship Form, and
· ICMJE Disclosure Form (should be filled in by all contributing authors).
Preparation of the Manuscript
Title page: A separate title page should be submitted with all submissions and this page should include:
• The full title of the manuscript as well as a short title (running head) of no more than 50 characters,
• Name(s), affiliations, highest academic degree(s), and ORCID IDs of the author(s),
• Grant information and detailed information on the other sources of support,
• Name, address, telephone (including the mobile phone number), and email address of the corresponding author,
• Acknowledgment of the individuals who contributed to the preparation of the manuscript but who do not fulfill the authorship criteria.
• If the author(s) is a member of the journal’s Editorial Board, this should be specified in the title page.
Abstract: An abstract should be submitted with all submissions except for Letters to the Editor. The abstract of Research Articles should be structured with subheadings (Objective, Methods, Results, and Conclusion). Please check Table 1 below for word count specifications.
Keywords: Each submission must be accompanied by a minimum of three to a maximum of six keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (https://www.nlm.nih.gov/mesh/MBrowser.html).
Manuscript Types
Research Articles
Research articles provide new information based on original research. The acceptance of research articles is typically based on the originality and importance of the research. The main text of a Research Article should be structured with subheadings, including Introduction, Methods, Results, Discussion, Conlusion and Recommendations.
Please check Table 1 for the limitations for Research Articles. You can review the ethical principles flow chart for research articles here.
Clinical Trials
Recent Trends in Pharmacology adopts the ICMJE's clinical trial registration policy, which requires that clinical trials must be registered in a publicly accessible registry that is a primary register of the WHO International Trials Registry Platform (ICTRP) or in ClinicalTrials.gov. By registering clinical trials in a publicly accessible registry, authors can help to promote transparency and accountability in their research.
Instructions for the clinical trials are listed below.
• Clinical trial registry is only required for the prospective research projects that study the relationship between a health-related intervention and an outcome by assigning people to different groups.
• To have their manuscript evaluated in the journal, authors should register their research to a public registry at or before the time of first patient enrollment.
• Based on most up to date ICMJE recommendations, Recent Trends in Pharmacology accepts public registries that include minimum acceptable 24-item trial registration dataset.
• Authors are required to state a data sharing plan for the clinical trial registration. Please see details under the “Data Sharing” section.
• For further details, please check ICMJE Clinical Trial Policy and COPE Data and Reproducibility guidelines.
Reporting Statistical Analysis
Statistical analysis to support conclusions is usually necessary. Statistical analyses must be conducted in accordance with international statistical reporting standards (Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. Br Med J 1983: 7; 1489-93). Information on statistical analyses should be provided with a separate subheading under the Methods section and the statistical software that was used during the process must be specified.
When reporting statistical data in a research paper, it is important to present the values in a clear and consistent manner. P values, confidence intervals (CIs), and other statistical measures should be rounded appropriately and expressed according to the guidelines provided. For example, p values should be expressed to two digits to the right of the decimal point unless the first two digits are zeros, in which case three digits should be provided (eg, instead of p < .01, report as p = .002). However, values close to .05 may be reported to three decimal places because .05 is an arbitrary cut-off point for statistical significance (eg, p = .053). P values less than .001 should be designated as p < .001 rather than providing the exact value (eg, p = .000006).
Units should be prepared in accordance with the International System of Units (SI).
Review Articles
Review articles that are written by authors with extensive knowledge and expertise in a particular field and a strong track record of publication are welcomed. These authors may even be invited to contribute a review article to the journal. Review articles should provide a comprehensive overview of the current state of knowledge on a topic in clinical practice, and should include discussions and evaluations of relevant research. The subheadings of the review articles can be planned by the authors. However, each review article should include an “Introduction” and a “Conclusion” section.
Please check Table 1 for the limitations for Review Articles.
Meta-analysis
Meta-analysis papers address topical clinical, scientific, ethical, and policy issues that matter to doctors, patients and health policy makers. These articles present a clearly reasoned argument, are backed by an even-handed look at the evidence, and have a clear key message. Articles that set out hypotheses are not suitable unless they contain a convincing attempt to test them.
Please check Table 1 for the limitations for Meta-analysis.
Case Reports
The journal has limited space for case reports, and prioritizes publishing reports on rare cases or challenging conditions that provide new insights into diagnosis and treatment, offer novel therapies, or reveal knowledge not yet included in the literature. Interesting and educational case reports are also welcomed for publication. The text of a case report should include Introduction, Case Presentation, and Discussion sections. An unstructured abstract should also be included. Please check Table 1 for the limitations for Case Reports.
Letters to the Editor
A "Letter to the Editor" is a type of manuscript that discusses important or overlooked aspects of a previously published article. This type of manuscript may also present articles on subjects within the scope of the journal that are of interest to readers, particularly educational cases. Readers can also use the "Letter to the Editor" format to share their comments on published manuscripts. The text of a "Letter to the Editor" should be unstructured and should not include an abstract, keywords, tables, figures, images, or other media. The manuscript that is being commented on must be properly cited within the "Letter to the Editor."
Table 1. Limitations for each manuscript type
| Type of manuscript | Word limit | Abstract word limit | Reference limit | Table limit | Figure limit |
| Research Article | 4000 | 350 (Structured) | 35 | 6 | 5 or total of 20 images |
| Review Article | 5000 | 350 | 50 | 6 | 10 or total of 30 images |
| Meta-analysis | 6000 | 350 | 70 | 10 | 10 or total of 15 images |
| Case Report | 1200 | 200 | 15 | No tables | 4 or total of 8 images |
| Letter to the Editor | 400 | No abstract | 5 | No tables | No media |
*Word limit should not include the abstract, references, tables, and figure legends.
Tables
Tables should be included in the main document, after the reference list, and they should be numbered consecutively in the order they are referred to within the text. Each table should have a descriptive title placed above it, and any abbreviations used in the table should be defined below the table by footnotes (even if they are defined in the main text). Tables should be created using the "insert table" command of the Word processing software, and they should be arranged clearly to make the data easy to read and understand. The data presented in the tables should not be a repetition of the data presented in the main text, but should support and enhance the main text.
Figures and Figure Legends
Figures should be submitted as separate files in TIFF or JPEG format, and they should not be embedded in the Word document or the main manuscript file. If a figure has subunits, each subunit should be submitted as a separate file, and the subunits should not be merged into a single image. The figures should not be labeled (a, b, c, etc.) to indicate subunits. Instead, the figure legend should be used to describe the different parts of the figure. Thick and thin arrows, arrowheads, stars, asterisks, and similar marks can be used on the images to support figure legends.Images should be anonymized to remove any information that may identify individuals or institutions. The minimum resolution of each figure should be 300 DPI, and the figures should be clear and easy to read. Figure legends should be listed at the end of the main document. Figures should be referred to within the main text, and they should be numbered consecutively in the order in which they are mentioned.
Abbreviations
All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition, and it should be used consistently throughout the paper.
Identifying products
When mentioning a drug, product, hardware, or software program in a manuscript, it is important to provide detailed information about the product in parentheses. This should include the name of the product, the producer of the product, and the city and country of the company. For example, if mentioning a Discovery St PET/CT scanner produced by General Electric in Milwaukee, Wisconsin, USA, the information should be presented in the following format: "Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA)." Providing this information helps to ensure that the product is properly identified and credited.
Supplementary Materials
Supplementary materials, including audio files, videos, datasets, and additional documents (e.g., appendices, additional figures, tables), are intended to complement the main text of the manuscript. These supplementary materials should be submitted as a separate section after the references list. Concise descriptions of each supplementary material should be included to explain their relevance to the manuscript. Page numbers are not required for supplementary materials.
References
Both in-text citations and the references must be prepared according to the Publication Manual of the American Psychological Association (APA), Seventh Edition (2020).
When citing publications, preference should be given to the latest, most up-to-date sources. Citing the latest sources can help to ensure that the paper is relevant and timely, and that it reflects the latest developments in the field.
It is the responsibility of the authors to ensure the accuracy of the references in their article. All sources must be properly cited, and the citations must be formatted correctly.
To avoid plagiarism, it is necessary to acknowledge other sources in your paper through in-text citations. For every in-text citation, a corresponding reference list entry must be provided.
The APA in-text citation style includes the author's last name and the year of publication, such as (Field, 2005). If quoting directly from a source, the page number should also be added, such as (Field, 2005, p. 14).
If an ahead-of-print publication is cited, the DOI number should be provided in the reference list.
The reference styles for different types of publications are presented in the following examples.
Journal Article: Edwards, A. A., Steacy, L. M., Siegelman, N., Rigobon, V. M., Kearns, D. M., Rueckl, J. G., & Compton, D. L. (2022). Unpacking the unique relationship between set for variability and word reading development: Examining word- and child-level predictors of performance. Journal of Educational Psychology, 114(6), 1242–1256. https://doi.org/10.1037/edu0000696
Book Section: Zeleke, W. A., Hughes, T. L., & Drozda, N. (2020). Home–school collaboration to promote mindbody health. In C. Maykel & M. A. Bray (Eds.), Promoting mind–body health in schools: Interventions for mental health professionals (pp. 11–26). American Psychological Association. https://doi.org/10.1037/0000157-002
Books with a Single Author: Haslwanter, T. (2022). An introduction to statistics with Python. New York, NY: Springer International Publishing.
Editor(s) as Author: Rhodewalt, F. (Ed.). (2008). Personality and social behavior. Psychology Press.
Thesis: Valentin, E. R. (2019, Summer). Narcissism predicted by Snapchat selfie sharing, filter usage, and editing [Master's thesis, California State University Dominguez Hills]. CSU ScholarWorks. https://scholarworks.calstate.edu/concern/theses/3197xm925?locale=en
Websites: Chandler, N. (2020, April 9). What’s the difference between Sasquatch and Bigfoot? howstuffworks. https://science.howstuffworks.com/science-vs-myth/strange-creatures/sasquatch-bigfootdifference.htm
Epub Ahead of Print Articles: Muldoon, K., Towse, J., Simms, V., Perra, O., & Menzies, V. (2012). A longitudinal analysis of estimation, counting skills, and mathematical ability across the first school year. Developmental Psychology. Epub ahead of print. doi:10.1037/a0028240.
In the seventh edition, up to 20 authors should now be included in a reference list entry. For sources with more than 20 authors, after the 19th listed author, any additional authors' names are replaced with an ellipsis (…) followed by the final listed author's name:
Author, A. A., Author, B. B., Author, C. C., Author, D. D., Author, E. E., Author, F. F., Author, G. G., Author, H. H., Author, I. I., Author, J. J., Author, K. K., Author, L. L., Author, M. M., Author, N. N., Author, O. O., Author, P. P., Author, Q. Q., Author, R. R., Author, S. S., . . . Author, Z. Z.
Production
Once a manuscript has been accepted for publication, it goes through a copy-editing process by professional language editors to ensure that it is clear and well-written. This process may involve correcting grammar, punctuation, and formatting errors, as well as making changes to improve the overall clarity and readability of the manuscript.
After the copy-editing process is complete, the manuscript is published online as an "ahead-of-print" publication, which means that it is available to readers before it is included in a scheduled issue of the journal. This allows readers to access the latest research as soon as it becomes available.
Before the manuscript is officially published, the corresponding author is sent a PDF proof of the accepted manuscript for review. The corresponding author is asked to review the proof and approve it for publication within a specified time period, typically 2 days. This is an important step in the publication process, as it allows the author to catch any errors or make any final changes before the manuscript is published.
Ethical Principles and Publication Policy
Price Policy
Recent Trends in Pharmacology is funded by the Atatürk University. Authors are not required to pay any fees during the evaluation and publication process.
Indexes
Citation Indexes
Other Indexes
Journal Boards
Editor in Chief
İstanbul Üniversitesi İstanbul Tıp Fakültesi’nden 1999 yılında mezun oldu. Aynı yıl TUS sınavı sonrasında Atatürk Üniversitesi Tıp Fakültesi Tıbbi Farmakoloji Anabilim Dalında uzmanlık eğitimine başladı. 2003 yılında uzman ve ardından yardımcı doçent oldu. Haziran 2007 yılında doçentliğe ve Şubat 2013’te profesörlüğe yükseltildi.
2008 yılında beyin nörotransmitter ölçümü yapabilen Türkiye’deki ilk, Avrupa’daki 2. “Beyin Sensör Laboratuarı”nı Atatürk Üniversitesi Tıbbi Farmakoloji Anabilim Dalı’nda kurdu. Çok sayıda TÜBİTAK projesinde (1001/1003) yürütücülük yaptı. Bu projeler sonucunda nörotransmitter kaydı yapabilen “biyouyumlu ilk beyin elektrotları”nı ekibiyle birlikte üretti. Ayrıca yine ekibiyle birlikte beyin hastalıklarının teşhis ve tedavisinde kullanılacak dünyadaki ilk “beyin nörotransmitter düzeyi ölçebilen tıbbi cihaz”ını üretti. Elektrot ve cihazların ulusal ve uluslararası patent başvurularını yaptı.
Uluslararası SCI ve SCI-E kapsamındaki dergilerde 140 makalesi bulunmaktadır. Hacımüftüoğlu’nun editörlüğünü yaptığı kitabı yayınlanmıştır. Nature (Springer) Lipids in Health and Disease dergisinde editör olarak görev yapmaktadır. Hacımüftüoğlu’nun, Google Scholar kayıtlarına göre son 1 yılda makalelerine 660 atıf yapılmıştır.
9 yüksek lisans, 14 doktora öğrencisi mezun etmiştir.
Hacımüftüoğlu, Türkiye’nin ilk ilaç adayı orijinal ürün ilaç patentlerini 2019, 2020 ve 2021 yıllarında Amerika, Japonya, Avrupa Birliği ve Kanada’dan almıştır. Bu ürün, Sağlık Bakanlığı ve Türk Patent Enstitüsüne göre etken maddesi ülkemizde keşfedilmiş ve patentleri alınmış ilk üründür. Hacımüftüoğlu’nun 5’i uluslararası olmak üzere toplam 15 patenti bulunmaktadır.
Ahmet Hacımüftüoğlu, Avrupa Sinir Bilim Federasyonu’nun (FENS) 2016’dan beri yönetim konseyi üyesi ve Türkiye temsilcisidir. 2019 FENS Sırbistan Kongresi’ni düzenleme görevini üstlenmiştir.
Hacımüftüoğlu, 2021 yılında Atatürk Üniversitesi Aşı Geliştirme ve Uygulama Merkezi Müdürlüğüne atanmıştır. Ülkemizin preklinik çalışmalardan başarıyla geçen aşılarından biri olan Atavaks aşısını ekibiyle birlikte üretmiştir. Aşı klinik çalışmalara girişi beklemektedir. Şu an Alzheimer Hastalığına yönelik aşı projesi ve çalışmalarını sürdürmektedir.
Aldığı Ödüller:
1. ISIF 2019 Altın Madalya, Bilim Sanayi ve Teknoloji Bakanlığı, 2019.
2. Birleşmiş Milletlere Bağlı Avrupa Fikri Mülkiyet Ödülü (Wipo Best Akademic, Wipo Ompi), 2019.
3. En iyi Doktora Tezi Hocası Ödülü, Atatürk Üniversitesi, 2014.
4. Atatürk Üniversitesi Sağlık Bilimleri Patent Dalında Birincilik Ödülleri (2011-2012-2013 yılları).
5. Atatürk Üniversitesi Sağlık Bilimleri Etkin Makale Dalında Birincilik Ödülü (2011).
6. Atatürk Üniversitesi Bilimsel Teşvik Ödülleri. İki dalda birincilik, bir dalda ikincilik (2019).
7. Tıp Fakültesi En Yüksek Akademik Puanı, 2019
8. Tıp Fakültesi En Yüksek Akademik Puanı, 2020
9. Tıp Fakültesi En Yüksek Akademik Puanı, 2021
Language Editor
Professor A. M. Abd El-Aty held prestigious positions at various renowned institutions across different countries. He served as a distinguished professor of pharmacology at Cairo University in Egypt and a high-level foreign talent professor at the College of Food Science and Engineering, Qilu University of Technology in China. Currently, he is appointed as a Foreign Professor at the Pharmacology Department, Faculty of Medicine, Ataturk University in Erzurum, Turkey, starting in January 2018. He is also a guest Professor at Binzhou Medical University, the affiliated Yantai Yuhuangding Hospital of Qiangdao University, and Shenzhen University General Hospital, China. Prior to his current position, from 2013 to January 2018, Professor Abd El-Aty was a Brain Pool Fellow at Chonnam National University in Gwangju, South Korea. During this time, he also served as a Foreign Professor at Konkuk University in Seoul, Republic of Korea. His primary research interest lies in the field of "natural and life sciences”. With an outstanding publication history, he has authored over 515 articles in esteemed journals, with 97.7% featuring international coauthorship. Notably, 53.3% (162 documents) rank among the top 25% most cited articles globally, and 56.9% (169 documents) are in the top 25% of journals on the basis of the CiteScore. His current h-index of 48 underscores the impact and significance of his research. Furthermore, he has contributed to 5 book chapters and participated in 6 projects funded by Korean institutes, serving as a consultant and/or participant.
In addition to his research endeavors, Professor Abd El-Aty holds prominent editorial roles. He is the Editor-in-Chief of the journal "Lipids in Health and Disease" and “Food Safety and Health” and has been associated with the Journal of Advanced Research as a Managing Editor for the past 10 years. He currently serves as an Associate Editor for the journal and holds the position of Academic Editor for PLOS ONE and Associate Editor for Frontiers in Nutrition - Food Chemistry Section. He is also an esteemed advisory board member of "Biomedical Chromatography and Separation Science Plus." Professor Abd El-Aty is recognized for his expertise globally and was appointed as a member of the Expert Roster of the Joint (FAO/WHO) Expert Committee on Food Additives from 2017--2027. Furthermore, he has been acknowledged as one of the top 2% of scientists in his field on the basis of a list compiled by Stanford University for the years 2020--2023.
For more details, please see the following links https://www.scopus.com/authid/detail.uri?authorId=57221356878
https://orcid.org/0000-0001-6596-7907
https://pubmed.ncbi.nlm.nih.gov/?term=Abd+el-aty+am&sort=date
http://www.fao.org/3/BS727EN/bs727en.pdf
Google Scholarhttps://scholar.google.co.kr/citations?user=v6_cgOwAAAAJ&hl=en
ResearcherID: H-8216-2018
Statistics Editor
Editorial Board
Dr. Öçsoy Yüksek Lisans (2011) ve Doktora (2014) çalışmalarını Amerika Birleşik Devletleri’nde University of Florida’da Nanobiyoteknoloji alanında önde gelen bilim insanı Prof. Dr. Weihong Tan danışmanlığında yapmıştır. Dr.Öçsoy, 2015 yılında Erciyes Üniversitesi (ERÜ) Eczacılık Fakültesine Yrd. Doç. olarak başlamıştır. 2015-2016 yıllarında University of Florida Agricultural and Biological Engineering Department Misafir öğretim üyesi olarak çalıştı. 2017 yılında Doçent ve 2023 Şubat’da Prof. Dr. olmuştur. Dr. Öçsoy’un dünyanın saygın dergileri başta olmak üzere yüksek etki faktörüne (EF) sahip dergilerde 130 civarında bilimsel makalesi bulunmaktadır. Bu yayınlardan 120 civarı ERÜ bünyesinde yapılmıştır. Nanobiyoteknoloji alanında davet üzerine saygın indeksli dergilere derlemeler ve yayın evlerine kitap bölümleri yazmıştır. Dr. Öçsoy, birçok Uluslararası, TÜBİTAK, TÜSEB, TAGEM, BAP ve özerk kuruluş projelerini başarı ile tamamlarken, birçok projeyi de devam ettirmektedir. Dr. Öçsoy’un bilimsel çalışmalarının evrensel bilime sağladığı en önemli katkı Nanoteknoloji ve Nano-biyoteknoloji alanındaki araştırma konularında oluşmaktadır. Dr. Öçsoy özellikle nano biyosensörlerin üzerine yaptığı araştırmalar ile Dünya Sağlık Örgütü'nün (WHO) 2015 ve 2022 yıllarında yayınladığı antibiyotik dirençli mikroorganizmalarla mücadele için küresel eylem planına katkılar sunmuştur. Ülkemizdeki hastanelerin tanı testlerini İTHAL etmesinden dolayı, Dr. Öçsoy ülkemizin millileştirme politikası kapsamında İTHAL tanı testlerini üretmiş, patent başvurularını tamamlamış. Bu tanı testleri katma değeri yüksek, yerli ve milli bir üretim ile ülke ekonomisine katkı sağlarken, gereksiz antibiyotik kullanımı ve enfeksiyonla mücadelede halk sağlığına büyük bir hizmet verecektir.
Dr. Öçsoy Mycobacterium tuberculosis üzerine yaptığı çalışma ve proje ile 2247-A Ulusal Lider Araştırmacılar Programı kapsamında 2022 Yılında Ulusal Lider Araştırmacı seçilerek Türkiye’de 31 Ulusal Lider Araştırmacıdan biri olma başarısını göstermiştir. Dr. Öçsoy 2022 yılında Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB) "Tıbbi Cihaz ve Tanı Kiti” Bilim Kurulu üyesi olarak seçilmiştir. Ayrıca, Dr. Öçsoy, Bilim ve Teknolojide Avrupa İş Birliği (European Cooperation in Science and Technology. COST’da 3 Aksiyonda Yönetim Komitesi (Management Committee-MC) üyesi olarak seçilmiştir.
Dr. Öçsoy’a evrensel bilime yaptığı katkılardan dolayı birçok ödül tevdi edilmiştir. Bazıları
2018 Yılı Türk Eczacıları Birliği Eczacılık Akademisi Teşvik Ödülü
2018 Yılı Türkiye Bilimler Akademisi (TÜBA) Üstün Başarılı Genç Bilim İnsanı (GEBİP) Ödülü (Tıp-Eczacılık Alanında)
2019 Yılı ODTÜ Prof. Dr. Mustafa Parlar Eğitim ve Araştırma Vakfı Araştırma Teşvik Ödülü (Tıp-Eczacılık Alanında)
2020 Yılı Bilim Akademisi (BAGEP) Genç Bilim İnsanları Ödülü (Tıp-Eczacılık Alanında)
2020 Yılı Bilim Kahramanları Derneği Yılın Bilim İnsanı Ödülü
2021 Yılı JCI-Türkiye TOYP (Türkiye'nin En Başarılı Genci) Ödüllerinde “Tıbbi Yenilik ve Buluşlar” kategorisinde TÜRKİYE BİRİNCİSİ
2022 Yılı Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB) Aziz Sancar Teşvik Ödülü.
2023 Yılı Sağlık Girişimi Ödülleri - Yılın Ar-Ge / İnovasyon Uygulaması Doctor Club Ödülü
2024 Yılı İslam İşbirliği Teşkilatı (İİT) Bilimsel ve Teknolojik İşbirliği Daimi Komitesinin Kimya alanında en iyi araştırma makale ödülü
2024 Yılı TÜBA-TEKNOFEST Doktora Bilim Ödülleri Doktora Tezi Ödülü (Danışman)
2025 Yılı Türk Eczacıları Birliği Eczacılık Akademisi Bilim Ödülü.
Dr. Zafer SEZER 1974 yılında Gümülcine’de doğdu. 1999’da İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi’nden mezun olduktan sonra 2005 yılında Erciyes Üniversitesi Tıp Fakültesi Farmakoloji Anabilim dalında ihtisasını tamamlamıştır. 2006 yılından beri aynı anabilim dalında görev yapmaktadır. 2008 yılından bu yana da Erciyes Üniversitesi Hakan Çetinsaya İyi Klinik Uygulama ve Araştırma Merkezi’nde (İKUM) gerçekleştirilen ulusal ve uluslararası ilaç firmalarının 1000’e yakın klinik ilaç araştırmasında sorumlu/yardımcı araştırmacı olarak görev almıştır. İlk yerli aşı TURKOVAC’ın geliştirilmesinde sorumlu araştırmacısı olduğu Faz 1 klinik araştırması yanısıra faz 2 ve 3 çalışmalarında da görev almıştır. Erciyes Üniversitesi Hakan Çetinsaya İyi Klinik Uygulama ve Araştırma Merkezi müdürlüğü ile birlikte Erciyes Üniversitesi Tıp Fakültesi Farmakoloji Anabilim Dalı Başkanlığını yürütmektedir.
